These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21585333)

  • 1. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.
    Milazzo L; Mazzali C; Bestetti G; Longhi E; Foschi A; Viola A; Vago T; Galli M; Parravicini C; Antinori S
    Curr HIV Res; 2011 Apr; 9(3):186-93. PubMed ID: 21585333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
    Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
    J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
    Petta S; Cammà C; Scazzone C; Tripodo C; Di Marco V; Bono A; Cabibi D; Licata G; Porcasi R; Marchesini G; Craxí A
    Hepatology; 2010 Apr; 51(4):1158-67. PubMed ID: 20162613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients.
    Guzmán-Fulgencio M; García-Álvarez M; Berenguer J; Jiménez-Sousa MÁ; Cosín J; Pineda-Tenor D; Carrero A; Aldámiz T; Alvarez E; López JC; Resino S
    J Infect; 2014 Feb; 68(2):176-84. PubMed ID: 24184809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.
    Mandorfer M; Payer BA; Schwabl P; Steiner S; Ferlitsch A; Aichelburg MC; Stättermayer AF; Ferenci P; Obermayer-Pietsch B; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2015 Mar; 35(3):876-85. PubMed ID: 24905495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.
    De Leon LB; Tovo CV; Kliemann DA; De Mattos AA; Feltrin AA; Pacheco LS; De Almeida PR
    J Infect Dev Ctries; 2016 Aug; 10(7):762-9. PubMed ID: 27482809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
    Mandorfer M; Neukam K; Reiberger T; Payer BA; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Meyer-Olson D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M
    AIDS; 2013 Nov; 27(17):2707-14. PubMed ID: 23835502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
    Berenguer J; von Wichmann MA; Quereda C; Miralles P; Mallolas J; López-Aldeguer J; Alvarez-Pellicer J; De Miguel J; Crespo M; Guardiola JM; Tellez MJ; Galindo MJ; Arponen S; Barquilla E; Bellón JM; González-García J;
    J Antimicrob Chemother; 2011 Dec; 66(12):2843-9. PubMed ID: 21965432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels.
    Avihingsanon A; Jitmitraparp S; Tangkijvanich P; Ramautarsing RA; Apornpong T; Jirajariyavej S; Putcharoen O; Treeprasertsuk S; Akkarathamrongsin S; Poovorawan Y; Matthews GV; Lange JM; Ruxrungtham K;
    J Gastroenterol Hepatol; 2014 Sep; 29(9):1706-14. PubMed ID: 24730732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
    Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.
    Neukam K; Almeida C; Caruz A; Rivero-Juárez A; Rallón NI; Di Lello FA; Herrero R; Camacho A; Benito JM; Macías J; Rivero A; Soriano V; Pineda JA
    J Antimicrob Chemother; 2013 Apr; 68(4):915-21. PubMed ID: 23243129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
    Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
    J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.